Skip to main content

Advertisement

SpringerLink
Log in

Etodolac in the management of pain: A clinical review of a multipurpose analgesic

  • Short Communication
  • Published:
InflammoPharmacology Aims and scope Submit manuscript

Abstract

Etodolac is a non-steroidal anti-inflammatory drug with analgesic properties. Its primary anti-inflammatory mechanism of action is through a selective effect on cyclo-oxygenase-2 (COX-2). It is rapidly absorbed after oral administration, and maximum plasma concentration (Cmax) is reached in 1-2 h, with an elimination half-life (t1/2 ) of 6-8 h.

Etodolac has been widely applied in the treatment of inflammatory arthritides such as rheumatoid arthritis, ankylosing spondylitis and gout and in osteoarthritis and has been shown to be efficacious and well tolerated.

However, etodolac has other applications which rely primarily on its efficacy as an analgesic. In particular, etodolac has been evaluated in the treatment of a variety of different pain states. Etodolac has been observed to be efficacious in the treatment of acute pain following dental extraction, orthopaedic and urological surgery, and episiotomy, as well as in the treatment of pain due to acute sports injuries, primary dysmenorrhoea, tendonitis, bursitis, periarthritis, radiculalgia and low back pain.

These studies indicate that etodolac is a multipurpose analgesic with many clinical applications in addition to its use in the treatment of inflammatory and degenerative forms of arthritis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Humber LG. Etodolac: The chemistry, pharmacology, metabolic dispositon, and clincial profile of a novel anti-inflammatory pyranocarboxylic acid. Med Res Rev. 1987;7(l):l-28.

    Google Scholar 

  2. Zvaifler N. A review of the antiarthritic efficacy and safety of etodolac. Clin Rheumatol. 1989;8(Suppl l):43–53.

    Article  PubMed  Google Scholar 

  3. Balfour JA, Buckley MM. Etodolac: A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states. Drugs. 1991;42(2):274–99.

    Article  PubMed  CAS  Google Scholar 

  4. Rainsford KD. The mode of action of azapropazone in relation to its therapeutic actions in rheumatic conditions and its major side effects. In: Rainsford KD, ed. Azapropazone: 20 Years of Clinical Use. Kluwer Academic Publishers, Lancaster. 1989;31–51.

    Google Scholar 

  5. Kaplan HB, Edelson HS, Korchak HM et al. Effect of non-steroidal anti-inflammatory agents on humana neutrophil function in vitro and in vivo. Biochem Pharmacol. 1984;33:371–8.

    Article  PubMed  CAS  Google Scholar 

  6. Glaser KB. Cyclooxygenase selectivity and NSAIDs: Cyclooxygenase-2 selectivity of etodolac (Iodine). Inflammopharmacology. 1995;3:335–45.

    Article  CAS  Google Scholar 

  7. Sirois P, Saura C, Salari H et al. Comparative effects of etodolac, indomethacin, and benoxaprofen on icosanoid biosynthesis. Inflammation. 1984;8(4):353–64.

    Article  PubMed  CAS  Google Scholar 

  8. Brocks DR, Jamali F. Etodolac clinical pharmacokinetics. Clin Pharmacokinet. 1994;26(4):259–74.

    PubMed  CAS  Google Scholar 

  9. Benet LZ. Pharmacokinetic profile of etodolac in special populations. Eur J Rheumatol Inflam. 1994;14(l):15–8.

    CAS  Google Scholar 

  10. Bacon PA. Safety profile of etodolac in the elderly population. Eur J Rheumatol Inflam. 1994; 14(1): 19- 22.

    Google Scholar 

  11. Schattenkirchner M. An updated safety profile of etodolac in several thousand patients. Eur J Rheumatol Inflamm. 1990;10:56–65.

    PubMed  CAS  Google Scholar 

  12. Compendium of Pharmaceuticals and Specialties. Toronto, Canadian Pharmaceutical Association. 1996; 1538–9.

  13. Cooper SA. Models for clinical assessment of oral analgesics. Am J Med. 1983;75(5A):24–9.

    Article  PubMed  CAS  Google Scholar 

  14. Scott R, Ellis III E, Upton LG. Double-blind evaluation of etodolac (200 mg, 400 mg) compared with zomepirac (100 mg) and placebo on third molar extraction pain. Oral Surg. 1986;66(6):638–42.

    Article  Google Scholar 

  15. Nelson SL, Bergman SA. Relief of dental surgery pain: a controlled 12-hour comparison of etodolac, aspirin, and placebo. Anesth Prog. 1985:151–6.

  16. Hutton CE. The effectiveness of 100 and 200 mg etodolac (Ultradol), aspirin, and placebo in patients with pain following oral surgery. Oral Surg. 1983;56(6):575–80.

    Article  PubMed  CAS  Google Scholar 

  17. Gaston GW, Mallow RD, Frank JE. The efficacy of etodolac for patients with pain following oral surgery. J Oral Maxillofac Surg. 1984;42:362–66.

    Article  PubMed  CAS  Google Scholar 

  18. Giglio JA, Campbell RL. Comparison of etodolac, zomepirac, and placebo for relief of pain after oral surgery. J Oral Maxillofac Surg. 1986;44:765–70.

    Article  PubMed  CAS  Google Scholar 

  19. Gaston GW, Mallow RD, Frank JE. Comparison of etodolac, aspirin and placebo for pain after oral surgery. Pharmacotherapy. 1986;6(5):199–204.

    PubMed  CAS  Google Scholar 

  20. Fliedner L, Levsky M, Kechejian H. Analgesia with etodolac in oral postsurgical pain. Curr Ther Res. 1984;36(l):33–45.

    Google Scholar 

  21. Pena M. Etodolac: analgesic effects in musculoskeletal and postoperative pain. Rheumatol Int. 1990;10(Suppl):9–16.

    Google Scholar 

  22. Mizraji M. Clinical response to etodolac in the management of pain. Eur J Rheumatol Inflamm. 1990;10(10):35–43.

    PubMed  CAS  Google Scholar 

  23. Versichelen L, Bilsback P, Roily G et al. Etodolac in postsurgical pain: a double-blind dose-ranging efficacy study with aspirin and placebo. Int J Clin Pharmacol Ther Toxicol. 1982;20(5):236–9.

    PubMed  CAS  Google Scholar 

  24. Bilsback P, Roily G, Versichelen L et al. Etodolac in postsurgical pain: Double-blind, dose-ranging efficacy study with aspirin and placebo. Cardiol Meas Anaesth. 1982;2:257–60.

    Google Scholar 

  25. Roily G, Bilsback P, Versichelen L et al. Etodolac in postoperative pain: a double-blind study with aspirin and placebo. Br J Anaesth.1982;54:250-l.

    Google Scholar 

  26. Friedrich E. A comparison of etodolac (Ultradol) with aspirin and placebo in patients with episiotomy pain. CurrTherap Res. 1983;33(l):100–7.

    Google Scholar 

  27. D’Hooghe M. Double-blind, parallel-group evaluation of etodolac and naproxen in patients with acute sports injuries. Clin Ther. 1992;14(4):507–16.

    PubMed  CAS  Google Scholar 

  28. Menkes CJ. Scapulo-humeral periarthritis: efficacy, safety and therapeutic benefit of etodolac (600 mg/ daily) versus piroxicam (40/20 mg/daily). Rhumatologie. 1990;42(7a):207–12.

    Google Scholar 

  29. Bontoux D. Lumbo-radiculalgia: efficacy, safety and therapeutic benefit of etodolac (600 mg/daily) versus diclofenac (150 mg/daily) and placebo. Rheumatologie. 1990;42(7a):213–18.

    Google Scholar 

  30. Davoli L, Ciotti G, Biondi M, Passeri M. Piroxicam-beta-cyclodextrin in the treatment of low-back pain. CurrTher Res. 1989;46(5):940–7.

    Google Scholar 

  31. Zecchi de Souza A Tacla M, Hegg R et al Etodolac in Primary dsysmenorrhoea. J Bras Ginecol 1991;101:451–9.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Western Ontario, London, Canada

    N. Bellamy

Authors
  1. N. Bellamy
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bellamy, N. Etodolac in the management of pain: A clinical review of a multipurpose analgesic. Inflammopharmacol 5, 139–152 (1997). https://doi.org/10.1007/s10787-997-0023-8

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10787-997-0023-8

Keywords

Search

Navigation